- Patients who received galcanezumab for the prevention of migraine had a significantly higher response rate and a bigger reduction in migraine headache days (MHD) than those receiving placebo.
Why this matters
- The majority of patients reported onset of efficacy within the first week of galcanezumab treatment, with a sustained response throughout the 3-month treatment period.
- Post hoc analysis of a randomized, double-blind phase 2a study.
- 217 patients with migraine received galcanezumab injection every 2 weeks (n=107) or placebo (n=110) for 12 weeks.
- Funding: Eli Lilly and Company.
- Significantly higher response rate in galcanezumab group at week 1 compared with placebo (62% vs 42%; P<.05>
- Significant decrease in weekly MHD with galcanezumab at week 1 compared with placebo (−0.89 vs −0.53; P=.018) that remained significant, except in weeks 6 and 9 (P<.05>
- 47% of patients responding to galcanezumab within 1 month maintained that response through months 2 and 3 (vs placebo, 25%).
- Among galcanezumab nonresponders at month 1, 27% responded at months 2 and 3 (vs placebo, 20%).
- Among galcanezumab nonresponders in months 1 and 2, 50% responded at month 3 (vs placebo, 24%).
- Original study not designed to measure weekly efficacy outcomes.